https://www.selleckchem.com/products/cl-82198.html
dpoint is the mean %HbF after 6 months of hydroxyurea. HOPS will answer important questions about the clinical feasibility, benefits, and safety of PK-guided dosing of hydroxyurea for children with SCD with potential to change the treatment paradigm from a standard weight-based approach to one that safely and effectively optimize the laboratory and clinical response. ClinicalTrials.gov NCT03789591 . Registered on 28 December 2018. ClinicalTrials.gov NCT03789591 . Registered on 28 December 2018. The success rate of implant-supported pro
Curtir
Comentario
Compartilhar
